Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptidomimetic thrombin inhibitors.

Danijel Kikelj1

  • 1University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia. danijel.kikelj@ffa.uni-lj.si

Pathophysiology of Haemostasis and Thrombosis
|February 5, 2005
PubMed
Summary

Researchers are developing new direct thrombin inhibitors, which are small molecules targeting thrombin in blood clotting. The goal is oral medications for effective antithrombotic therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New ATP-competitive inhibitors of <i>E. coli</i> GyrB obtained from the mapping of the hydrophobic floor at the binding site: synthesis and biological evaluation.

RSC medicinal chemistry·2024
Same author

New <i>N</i>-phenylpyrrolamide inhibitors of DNA gyrase with improved antibacterial activity.

RSC advances·2024
Same author

Improved N-phenylpyrrolamide inhibitors of DNA gyrase as antibacterial agents for high-priority bacterial strains.

European journal of medicinal chemistry·2024
Same author

Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria.

European journal of medicinal chemistry·2024
Same author

Exploring the interaction of N-(benzothiazol-2-yl)pyrrolamide DNA gyrase inhibitors with the GyrB ATP-binding site lipophilic floor: A medicinal chemistry and QTAIM study.

Bioorganic & medicinal chemistry·2024
Same author

Estimation of passive gastrointestinal absorption of new dual DNA gyrase and topoisomerase IV inhibitors using PAMPA and biopartitioning micellar chromatography and quantitative structure-retention relationship analysis.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2024

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Thrombin is a key enzyme in the coagulation cascade, making it a significant target for antithrombotic drug development.
  • The discovery of direct thrombin inhibitors began with natural peptides like hirudin and has evolved to synthetic small molecules.
  • Peptidomimetics, designed based on fibrinogen's structure, are a major class of these inhibitors.

Purpose of the Study:

  • To review the progress and advancements in the discovery of direct thrombin inhibitors.
  • To highlight structure-based design strategies utilizing X-ray crystallography.
  • To discuss the development of orally bioavailable small-molecule inhibitors for convenient dosing.

Main Methods:

  • Review of literature on direct thrombin inhibitors.
  • Analysis of structure-activity relationships informed by X-ray crystallography of thrombin-inhibitor complexes.
  • Overview of advanced peptidomimetic inhibitors including bivalirudin, argatroban, ximelagatran, and dabigatran.

Main Results:

  • Hundreds of direct thrombin inhibitors have been discovered over the past two decades.
  • Structure-based design has significantly aided the development of low-molecular-weight peptidomimetic inhibitors.
  • Several advanced inhibitors are nearing the goal of oral bioavailability for daily dosing.

Conclusions:

  • Direct thrombin inhibitors represent a promising class of antithrombotic agents.
  • Continued research focuses on optimizing these inhibitors for improved efficacy and patient convenience.
  • The development of orally administered direct thrombin inhibitors is a key objective in antithrombotic therapy.

Related Experiment Videos